One of the most common questions I get is: "Is this peptide causing my constipation?" The answer is: Sometimes yes. Sometimes no. And sometimes the peptide is only part of the story. When people think of peptide-related constipation, they're usually talking about GLP-1 medications such as: • Semaglutide • Tirzepatide • Retatrutide • Survodutide These compounds slow gastric emptying, meaning food moves through the digestive tract more slowly. This is one of the reasons they work so well for appetite control and weight loss. The downside? Slower digestion can sometimes lead to: • Constipation • Bloating • Fullness • Gas • Abdominal discomfort Many people assume the medication itself is the only cause. In reality, several things often happen at the same time: You're Eating Less When food intake drops significantly, stool volume often drops too. Less food in = less waste out. Or as I like to tell people: "You can't poop what you didn't eat." I know it's not the most glamorous explanation, but it's true. Many people go from eating three meals and snacks every day to eating a fraction of what they used to consume. Naturally, there is going to be less material moving through the digestive tract. You're Drinking Less Many people on GLP-1s don't just lose their appetite. They lose their thirst, too. Dehydration is one of the most common contributors to constipation. You're Not Getting Enough Fiber When appetite decreases, fruits, vegetables, and other fiber sources are often the first foods people stop eating. You're Not Moving Enough Physical activity helps stimulate normal bowel function. The less you move, the slower things can become. Peptides Besides GLP-1s While GLP-1s get most of the blame, constipation can occasionally occur with other peptides if: • Food intake decreases significantly • Hydration is inadequate • Physical activity declines • Other supplements or medications contribute In many cases, the peptide isn't directly causing the constipation—it's the changes in eating and drinking habits that occur while using it.

Sorry the pic is so small......do not respond to any DM's from this bonehead. Complete scammer! I've already banned him form the group but he may have been able to send out some DM's before this.

I wanted to share a real-time update with you guys since I know a lot of you are curious about stacking + micro-dosing strategies: Current Protocol (for transparency)- - Retatrutide: 0.5 mg→ Wednesday + Friday - Tirzepatide: 7 mg→ Monday What I’m Noticing So Far- Appetite / Food Behavior: - Zero cravings… like NONE - I literally don’t want anything - I can’t finish a plate of food - Actually having to force myself to eat This is way stronger appetite suppression than what I’ve ever experienced before. Body Changes (Already ): - Rings are feeling looser - Pants are feeling looser This early tells me there’s likely: - Rapid inflammation drop - Possible water weight shift - Early fat loss starting Side Effect Check: - Leg fatigue was pretty intense three nights ago and carried into the next day. Better yesterday and today, but still noticeable. My Take So Far: This combo is VERY potent—even at micro-dose levels. What stands out most: - Appetite suppression is on another level - You will need to be intentional about eating enough - Your body is clearly shifting metabolically very quickly When you hit the point of: - No hunger - No cravings - Struggling to eat That’s not always a flex—it can become a problem if you’re under-fueling Things I’m personally paying attention to: - Getting enough protein - Staying hydrated - Electrolytes (especially with that leg fatigue) What I’m Watching Moving Forward: - Energy levels - Muscle retention - Continued side effects (especially fatigue) - How sustainable this feels I Want to Hear From You: - Anyone else experimenting with micro-dosing strategies? - Have you noticed stronger suppression with stacking vs solo? - Anyone experience leg fatigue like this? Drop your experience below let’s compare notes! Disclaimer: This is my personal experience only — not medical advice.Everyone responds differently, especially with compounds like these.

https://people.com/mental-health-benefits-may-be-linked-to-glp-1-weight-loss-drugs-in-new-study-11932901

When considering semaglutide (GLP-1 agonist), tirzepatide (GLP-1/GIP dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist), contraindications can be grouped into several practical categories. ABSOLUTE contraindications are situations where the drug should not be used because the risk clearly outweighs any benefit; for all three incretin-based agents this includes a personal or family history of medullary thyroid carcinoma or MEN2, prior serious hypersensitivity to the drug, and generally pregnancy. RELATIVE contraindications are conditions where use may be possible but requires caution and close monitoring, such as severe gastrointestinal disease (e.g., gastroparesis), history of pancreatitis, gallbladder disease, advanced frailty, or high risk of dehydration; these concerns tend to be mildest with semaglutide, more notable with tirzepatide, and potentially greater with retatrutide because its added glucagon activity increases metabolic stress. TEMPORARY contraindications are short-term reasons to hold therapy, such as acute severe nausea/vomiting, dehydration, acute pancreatitis workup, or before major surgery where slowed gastric emptying could increase aspiration risk. PERMANENT contraindications include MEN2, medullary thyroid carcinoma, or a proven severe allergic reaction to the medication. DIRECT contraindications are problems caused by the drug’s own mechanisms, such as worsening gastroparesis, severe GI intolerance, or recurrent pancreatitis, while INDIRECT contraindications arise from downstream effects like volume depletion, electrolyte imbalance, or excessive lean mass loss if nutrition is poor. DISEASE-DRUG contraindications include conditions like severe gastroparesis, certain endocrine tumor syndromes, or unstable pancreatitis history, and procedural contraindications mainly involve holding these agents before anesthesia or endoscopy due to delayed gastric emptying. So, semaglutideis usually the most conservative and predictable option, tirzepatide offers greater metabolic effect with similar but sometimes stronger GI risks, and retatrutide is the most potent and potentially most stressful metabolically, so it demands the greatest caution, slow titration, and careful patient selection. If you are not sure where you are in the scheme of your own therapy, consult your PCP to go over potential contraindications before you start your RS journey. The more you know.